<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="33078a1f-ddf4-1485-c75f-edcafd3f27e3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.</content>
      <br/>
      <br/>
      <content styleCode="bold">TRAZODONE HYDROCHLORIDE tablets, for oral use</content>
      <content styleCode="bold">
         <br/>
         <content styleCode="bold">Initial U.S. Approval: 1981</content>
      </content>
   </title>
   <effectiveTime value="20250320"/>
   <setId root="71961ab1-951d-1493-f76c-2ff25cca2a85"/>
   <versionNumber value="20"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="56e701d0-11d5-b506-2ad9-fa88511a48b4"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-2653" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Trazodone Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Trazodone Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6E8ZO8LRNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRAZODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YBK48BXK30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Trazodone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2653-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2653-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20200531"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-2653-0"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20081117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="17000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2653-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20200531"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA071258" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;T50</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-2654" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Trazodone Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Trazodone Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6E8ZO8LRNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRAZODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YBK48BXK30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Trazodone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2654-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2654-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20200531"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-2654-0"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20081117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="9000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2654-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20200331"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA071196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;T100</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-2655" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Trazodone Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Trazodone Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6E8ZO8LRNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRAZODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YBK48BXK30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Trazodone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2655-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2655-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20200630"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="5500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2655-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20081117"/>
                                    <high value="20190131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="3" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="17" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA071196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;T150;50;50;50</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4089" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Trazodone Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Trazodone Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6E8ZO8LRNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRAZODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YBK48BXK30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Trazodone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43170" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DISPENSING"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-4089-3"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20141231"/>
                                          <high value="20160930"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="3" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="17" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20141231"/>
                              <high value="20160930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA071196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;T150;50;50;50</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-2659" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Trazodone Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Trazodone Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6E8ZO8LRNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRAZODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YBK48BXK30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Trazodone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2659-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090105"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2659-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090105"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1400"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-2659-7"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090105"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="3" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090105"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA071196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;T300;100;100;100</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="c565b108-dcbc-363b-e558-7aa6eda218e6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20090930"/>
                     <component>
                        <observationMedia ID="MM989305667513">
                           <text>structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM557716188616">
                           <text>50mg-score</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="50mg-score.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM429238456859">
                           <text>100mg-score</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="100mg-score.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM701672054080">
                           <text>150mg-tablet</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="150mg-tablet.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM477102318795">
                           <text>100mg-break</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="100mg-break.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM713385749530">
                           <text>150mg-break</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="150mg-break.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM642721831157">
                           <text>200mg-break</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="200mg-break.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM593807962266">
                           <text>300mg-break</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="300mg-break.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM107749710029">
                           <text>50mg-100btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="50mg-100btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM554913463851">
                           <text>100mg-100btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="100mg-100btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM185815916677">
                           <text>150mg-100btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="150mg-100btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM57659932193">
                           <text>300mg-100btl.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="300mg-100btl.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM264852694410">
                           <text>Legacy-150mg-12x30-carton</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="Legacy-150mg-12x30-carton.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="BOXED_WARNING">
               <id root="ddc00ca0-3200-ad47-9b6a-0a3fb1b0b64f"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">WARNING: SUICIDAL THOUGHTS and BEHAVIORS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors </content>
                     <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)].</content>
                     <content styleCode="bold"> Trazodone hydrochloride tablets are not approved for use in pediatric patients </content>
                     <content styleCode="bold italics">[see Use in Specific Populations (<linkHtml href="#_0d30fd8a-cf84-c9dd-26ea-2b957071369e">8.4</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20221125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <list>
                           <item>
                              <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Trazodone hydrochloride tablets are not approved for use in pediatric patients (<linkHtml href="#_0d30fd8a-cf84-c9dd-26ea-2b957071369e">8.4</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_af02e9bf-76f5-1ecb-07a6-950fe2c75a28">
               <id root="363ab7f5-9e4d-4355-c671-92dc30d68ff6"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.</paragraph>
               </text>
               <effectiveTime value="20171129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Trazodone hydrochloride tablets are  a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) (<linkHtml href="#_af02e9bf-76f5-1ecb-07a6-950fe2c75a28">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">
               <id root="bd6ac095-6ac0-93cd-ce8f-4a3109d01a9b"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20181129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days. Maximum dose: 400 mg per day in divided doses (<linkHtml href="#_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">2</linkHtml>).</item>
                           <item>Trazodone hydrochloride tablets should be taken shortly after a meal or light snack (<linkHtml href="#_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">2</linkHtml>).</item>
                           <item>Tablets should be swallowed whole or broken in half along the score line, and should not be chewed or crushed (<linkHtml href="#_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">2</linkHtml>).</item>
                           <item>When discontinued, gradual dose reduction is recommended (<linkHtml href="#_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">2</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_9e25ca01-bb5b-cb67-2f9c-ca6fe67d2714">
                     <id root="e6f1447f-8b2b-da92-19c2-83823b1d9526"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Dose Selection</title>
                     <text>
                        <paragraph>An initial dose of 150 mg/day in divided doses is suggested. The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage.</paragraph>
                        <paragraph>The dose may be increased by 50 mg/day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided doses.</paragraph>
                        <paragraph>Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_1f90a97f-e824-bc5f-2fe2-e0d068945449">
                     <id root="08d41555-1097-21ce-2a66-26301139a03e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Important Administration Instructions</title>
                     <text>
                        <paragraph>Trazodone hydrochloride tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line.</paragraph>
                        <paragraph>Trazodone hydrochloride tablets should be taken shortly after a meal or light snack. </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_c8dfdc15-ea96-18b4-0f7b-97624c18a3d5">
                     <id root="2e3096e4-c36b-2aa9-a533-c614e3da1a41"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Screen for Bipolar Disorder Prior to Starting Trazodone Hydrochloride Tablets</title>
                     <text>
                        <paragraph>Prior to initiating treatment with trazodone hydrochloride tablets or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_5721d907-539e-4548-d3ca-2940e4c2af16">5.7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_9b11e965-1b64-f03b-b1b2-964a8b43597d">
                     <id root="0c8dc9e0-4585-a045-baaa-d4f58181f601"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Switching to or from Monoamine Oxidase Inhibitor Antidepressant</title>
                     <text>
                        <paragraph>At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of trazodone hydrochloride tablets. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant <content styleCode="italics">[see Contraindications (<linkHtml href="#_e2fc53b8-049e-0ed8-850a-0ad92a847db7">4</linkHtml>), Warnings and Precautions (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_a3d77fa7-a1fa-3c76-8509-132a71f296d7">
                     <id root="c42c0325-62d6-65b9-3910-6c50789c67f3"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inhibitors or Inducers</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Coadministration with Strong CYP3A4 Inhibitors</content>
                           <br/>Consider reducing trazodone dose based on tolerability when trazodone is coadministered with a strong CYP3A4 inhibitor <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Coadministration with Strong CYP3A4 Inducers</content>
                           <br/>Consider increasing trazodone dose based on therapeutic response when trazodone is coadministered with a strong CYP3A4 inducer <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_07ceaee9-d4d9-db51-6484-edef5063c3ae">
                     <id root="6f15d58c-a40a-8444-1086-2a0b00f9a80a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.6 Discontinuation of Treatment with Trazodone Hydrochloride Tablets</title>
                     <text>
                        <paragraph>Adverse reactions may occur upon discontinuation of trazodone hydrochloride tablets <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#_ce899574-ede6-067b-51f8-def9ab8193a1">5.8</linkHtml>)].</content> Gradually reduce the dosage rather than stopping trazodone hydrochloride tablets abruptly whenever possible.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_789bc879-fc16-cd6a-3567-ab2fe84b0103">
               <id root="fa80a962-48b2-7b41-0452-49da93255391"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Trazodone hydrochloride tablets, USP are available in the following strengths:</paragraph>
                  <paragraph>50 mg <content styleCode="bold">: </content>white, round, biconvex,  scored  tablets. Engraved “APO” bisect “T50” on one side, other side plain.</paragraph>
                  <paragraph>100 mg: white, round, biconvex, scored tablets. Engraved “APO” bisect “T100” on one side, other side plain.</paragraph>
                  <paragraph>150 mg: white, oval, flat faced beveled-edge scored tablets with a full bisect and 2 partial trisects. Engraved “APO” bisect “T150” on one side, and “50 50 50” on the other side.</paragraph>
                  <paragraph>300 mg: white, oval, flat faced beveled-edge scored tablets with a full bisect and 2 partial trisects. Engraved “APO” bisect “T300” on one side, and “100 100 100” on the other side with the middle “100” perpendicular to the others.</paragraph>
               </text>
               <effectiveTime value="20221124"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Scored tablets of 50 mg, 100 mg ,150 mg and 300 mg (<linkHtml href="#_789bc879-fc16-cd6a-3567-ab2fe84b0103">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_e2fc53b8-049e-0ed8-850a-0ad92a847db7">
               <id root="6a3e09e8-54d3-1481-be8b-bc29468fe80c"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Trazodone hydrochloride tablets are contraindicated in:</paragraph>
                  <list>
                     <item>Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>), Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20170731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs (<linkHtml href="#_e2fc53b8-049e-0ed8-850a-0ad92a847db7">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_a941d206-9b94-3870-dfeb-e1247514fe5f">
               <id root="e8231bfb-6270-4aec-1a21-3cde8af49db3"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20181129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue trazodone hydrochloride tablets and initiate supportive treatment (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>).</item>
                           <item>Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval (<linkHtml href="#_f741940d-8024-3f3c-bad5-7282639ad20b">5.3</linkHtml>).</item>
                           <item>Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension (<linkHtml href="#_6ad12a09-5174-a7b8-b333-b206ec9929d0">5.4</linkHtml>).</item>
                           <item>Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (<linkHtml href="#_a0b9d8cd-491b-71dd-95e2-ada75b696918">5.5</linkHtml>).</item>
                           <item>Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed (<linkHtml href="#_b6388094-f2da-47f5-7312-c218c50322fe">5.6</linkHtml>).</item>
                           <item>Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania (<linkHtml href="#_5721d907-539e-4548-d3ca-2940e4c2af16">5.7</linkHtml>).</item>
                           <item>Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery (<linkHtml href="#_d789bb9c-d58b-b9d1-7708-0e15cf5556fe">5.9</linkHtml>).</item>
                           <item>Angle-Closure Glaucoma: Avoid use of antidepressants, including trazodone hydrochloride tablets, in patients with untreated anatomically narrow angles (<linkHtml href="#_2dcaea47-ec4d-1317-97b3-cd56e58670fe">5.10</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_d4289aff-5958-dcf0-0440-cc71f7bc082d">
                     <id root="8d1f67fd-c7ad-8d78-51ae-7df623c46e7a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients</title>
                     <text>
                        <paragraph>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in <content styleCode="bold">Table 1</content>.</paragraph>
                        <paragraph>No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.</paragraph>
                        <table rules="all">
                           <tbody align="center">
                              <tr>
                                 <td align="left" colspan="2">
                                    <content styleCode="bold">Table 1: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Age Range (years)</td>
                                 <td>Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1,000 Patients Treated</td>
                              </tr>
                              <tr>
                                 <td colspan="2">Increases Compared to Placebo</td>
                              </tr>
                              <tr>
                                 <td>&lt;18</td>
                                 <td>14 additional patients</td>
                              </tr>
                              <tr>
                                 <td>18-24</td>
                                 <td>5 additional patients</td>
                              </tr>
                              <tr>
                                 <td colspan="2">Decreases Compared to Placebo</td>
                              </tr>
                              <tr>
                                 <td>25-64</td>
                                 <td>1 fewer patient</td>
                              </tr>
                              <tr>
                                 <td>≥65</td>
                                 <td>6 fewer patients</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression.</paragraph>
                        <paragraph>Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing trazodone hydrochloride tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20221125"/>
                  </section>
               </component>
               <component>
                  <section ID="_33c063b9-30e5-1254-930d-96a81239f17b">
                     <id root="0dbc3bcf-e9b1-c432-2e0c-aa4f0399f906"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Serotonin Syndrome </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics"/>Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including trazodone, can precipitate serotonin syndrome, a potentially life-threatening condition. The <content styleCode="bold">risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications(<linkHtml href="#_e2fc53b8-049e-0ed8-850a-0ad92a847db7">4</linkHtml>), Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)]. Serotonin syndrome can also occur when these drugs are used alone.</content>
                        </paragraph>
                        <paragraph>Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</paragraph>
                        <paragraph>The concomitant use of trazodone with MAOIs is contraindicated. In addition, do not initiate trazodone in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking trazodone hydrochloride tablets, discontinue trazodone before initiating treatment with the MAOI <content styleCode="italics">[see Contraindications (<linkHtml href="#_e2fc53b8-049e-0ed8-850a-0ad92a847db7">4</linkHtml>), Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor all patients taking trazodone for the emergence of serotonin syndrome. Discontinue treatment with trazodone and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of trazodone with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20221129"/>
                  </section>
               </component>
               <component>
                  <section ID="_f741940d-8024-3f3c-bad5-7282639ad20b">
                     <id root="5ab9f602-335d-660e-6793-f82d6ef65b0b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Cardiac Arrhythmias</title>
                     <text>
                        <paragraph>Clinical studies indicate that trazodone hydrochloride may be arrhythmogenic in patients with preexisting cardiac disease. Arrhythmias identified include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsade de pointes. Postmarketing events, including torsade de pointes have been reported at doses of 100 mg or less with the immediate-release form of trazodone. Trazodone should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval. Trazodone is not recommended for use during the initial recovery phase of myocardial infarction. Caution should be used when administering trazodone to patients with cardiac disease and such patients should be closely monitored, since antidepressant drugs (including trazodone) may cause cardiac arrhythmias <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_13047cbc-96a7-38fd-b59b-99bd03fe8f26">6.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Trazodone prolongs the QT/QTc interval. The use of trazodone should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). Concomitant administration of drugs may increase the risk of cardiac arrhythmia <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_6ad12a09-5174-a7b8-b333-b206ec9929d0">
                     <id root="3f0dd258-9ce3-4782-bc29-3a1902218e80"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Orthostatic Hypotension and Syncope</title>
                     <text>
                        <paragraph>Hypotension, including orthostatic hypotension and syncope has been reported in patients receiving trazodone hydrochloride. Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_a0b9d8cd-491b-71dd-95e2-ada75b696918">
                     <id root="615216e8-38d5-1483-1339-455c216651bb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Increased Risk of Bleeding</title>
                     <text>
                        <paragraph>Drugs that interfere with serotonin reuptake inhibition, including trazodone, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.</paragraph>
                        <paragraph>Inform patients about the risk of bleeding associated with the concomitant use of trazodone and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing trazodone.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_b6388094-f2da-47f5-7312-c218c50322fe">
                     <id root="0340b759-5e18-cafd-0312-9da7b7fe7da9"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Priapism</title>
                     <text>
                        <paragraph> Cases of priapism (painful erections greater than 6 hours in duration) have been reported in men receiving trazodone. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Men who have an erection lasting greater than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_13047cbc-96a7-38fd-b59b-99bd03fe8f26">6.2</linkHtml>), Overdosage (<linkHtml href="#_18861b9f-09eb-3b23-9780-609bc4fe1030">10</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Trazodone should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease).</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_5721d907-539e-4548-d3ca-2940e4c2af16">
                     <id root="ebe36595-4418-9154-b65b-fd811ecee148"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Activation of Mania or Hypomania</title>
                     <text>
                        <paragraph>In patients with bipolar disorder, treating a depressive episode with trazodone or another antidepressant may precipitate a mixed/manic episode. Activation of mania/hypomania has been reported in a small proportion of patients with major affective disorder who were treated with antidepressants. Prior to initiating treatment with trazodone, screen patients for any personal or family history of bipolar disorder, mania, or hypomania <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_c8dfdc15-ea96-18b4-0f7b-97624c18a3d5">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_ce899574-ede6-067b-51f8-def9ab8193a1">
                     <id root="18239476-adf3-1973-cb24-c6088f90043c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Discontinuation Syndrome</title>
                     <text>
                        <paragraph>Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible <content styleCode="italics">[See Dosage and Administration (<linkHtml href="#_07ceaee9-d4d9-db51-6484-edef5063c3ae">2.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_d789bb9c-d58b-b9d1-7708-0e15cf5556fe">
                     <id root="14f8d4e3-1d5f-8e19-bdfe-fc5d9b0d3ca7"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9 Potential for Cognitive and Motor Impairment</title>
                     <text>
                        <paragraph>Trazodone hydrochloride tablets may cause somnolence or sedation and may impair the mental and/or physical ability required for the performance of potentially hazardous tasks. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_2dcaea47-ec4d-1317-97b3-cd56e58670fe">
                     <id root="24cec44e-924a-3415-cea1-f489dc947588"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.10 Angle-Closure Glaucoma</title>
                     <text>
                        <paragraph>The pupillary dilation that occurs following use of many antidepressant drugs including trazodone hydrochloride may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including trazodone, in patients with untreated anatomically narrow angles.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_0bd0cb9b-1a1b-1fa6-8102-5bb19f200b4f">
                     <id root="2ccf2d44-f72b-4d7f-d067-1d004b7b02d2"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11 Hyponatremia</title>
                     <text>
                        <paragraph>Hyponatremia may occur as a result of treatment with SNRIs and SSRIs, including trazodone. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</paragraph>
                        <paragraph>In patients with symptomatic hyponatremia, discontinue trazodone and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#_57b1803e-40ca-bb02-a96b-bdff5f52927a">8.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_b2b1e02f-d71b-a63e-ac34-3cd3919ccf16">
               <id root="c39f6ee6-a1dd-cade-e61c-cf7f6bce9ba0"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list>
                     <item>Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)]</content>
                     </item>
                     <item>Serotonin Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>)]</content>
                     </item>
                     <item>Cardiac Arrythmias <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_f741940d-8024-3f3c-bad5-7282639ad20b">5.3</linkHtml>)]</content>
                     </item>
                     <item>Orthostatic Hypotension and Syncope <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_6ad12a09-5174-a7b8-b333-b206ec9929d0">5.4</linkHtml>)]</content>
                     </item>
                     <item>Increased Risk of Bleeding <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_a0b9d8cd-491b-71dd-95e2-ada75b696918">5.5</linkHtml>)]</content>
                     </item>
                     <item>Priapism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_b6388094-f2da-47f5-7312-c218c50322fe">5.6</linkHtml>)]</content>
                     </item>
                     <item>Activation of Mania or Hypomania <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_5721d907-539e-4548-d3ca-2940e4c2af16">5.7</linkHtml>)]</content>
                     </item>
                     <item>Discontinuation Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ce899574-ede6-067b-51f8-def9ab8193a1">5.8</linkHtml>)]</content>
                     </item>
                     <item>Potential for Cognitive and Motor Impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_d789bb9c-d58b-b9d1-7708-0e15cf5556fe">5.9</linkHtml>)]</content>
                     </item>
                     <item>Angle-Closure Glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_2dcaea47-ec4d-1317-97b3-cd56e58670fe">5.10</linkHtml>)]</content>
                     </item>
                     <item>Hyponatremia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_0bd0cb9b-1a1b-1fa6-8102-5bb19f200b4f">5.11</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20170731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥ 5% and twice that of placebo) are: edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, weight loss (<linkHtml href="#_b2b1e02f-d71b-a63e-ac34-3cd3919ccf16">6</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold italics">www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_34a4da9a-f125-7c63-7123-0e1585b543fa">
                     <id root="a5c0863c-cf01-166e-43e8-05906c2d33dd"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Common Adverse Reactions Occurring in ≥ 2% of Trazodone Hydrochloride Tablets-treated Patients and Greater than the Rate of Placebo-Treated Patients as Observed in Controlled Clinical Studies</content>
                        </paragraph>
                        <table frame="box" rules="all" width="50%">
                           <tbody align="center">
                              <tr>
                                 <td/>
                                 <td colspan="2">Inpatients</td>
                                 <td colspan="2">Outpatients</td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>Trazodone Hydrochloride Tablets <br/>N=142</td>
                                 <td>Placebo N=95</td>
                                 <td>Trazodone Hydrochloride Tablets <br/>N=157</td>
                                 <td>Placebo N=158</td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Allergic</content>
                                 </td>
                                 <td rowspan="2">
                                    <content styleCode="bold">　</content>3%</td>
                                 <td align="center" rowspan="2">
                                    <content styleCode="bold">　</content>1%</td>
                                 <td rowspan="2">
                                    <content styleCode="bold">　</content>7%</td>
                                 <td rowspan="2">
                                    <content styleCode="bold">　</content>1%</td>
                              </tr>
                              <tr>
                                 <td align="left">Skin Condition/Edema</td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Autonomic</content>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Blurred Vision</td>
                                 <td>6%</td>
                                 <td>4%</td>
                                 <td>15%</td>
                                 <td>4%</td>
                              </tr>
                              <tr>
                                 <td align="left">Constipation</td>
                                 <td>7%</td>
                                 <td>4%</td>
                                 <td>8%</td>
                                 <td>6%</td>
                              </tr>
                              <tr>
                                 <td align="left">Dry Mouth</td>
                                 <td>15%</td>
                                 <td>8%</td>
                                 <td>34%</td>
                                 <td>20%</td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">Cardiovascular</content>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Hypertension</td>
                                 <td>20%</td>
                                 <td>1%</td>
                                 <td>1%</td>
                                 <td>*</td>
                              </tr>
                              <tr>
                                 <td align="left">Hypotension</td>
                                 <td>7%</td>
                                 <td>1%</td>
                                 <td>4%</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Syncope</td>
                                 <td>3%</td>
                                 <td>2%</td>
                                 <td>5%</td>
                                 <td>1%</td>
                              </tr>
                              <tr>
                                 <td align="left">
                                    <content styleCode="bold">CNS</content>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Confusion</td>
                                 <td>5%</td>
                                 <td>0</td>
                                 <td>6%</td>
                                 <td>8%</td>
                              </tr>
                              <tr>
                                 <td align="left">Decreased Concentration</td>
                                 <td>3%</td>
                                 <td>2%</td>
                                 <td>1%</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Disorientation</td>
                                 <td>2%</td>
                                 <td>0</td>
                                 <td>*</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Dizziness/Light-Headedness</td>
                                 <td>20%</td>
                                 <td>5%</td>
                                 <td>28%</td>
                                 <td>15%</td>
                              </tr>
                              <tr>
                                 <td align="left">Drowsiness</td>
                                 <td>24%</td>
                                 <td>6%</td>
                                 <td>41%</td>
                                 <td>20%</td>
                              </tr>
                              <tr>
                                 <td align="left">Fatigue</td>
                                 <td>11%</td>
                                 <td>4%</td>
                                 <td>6%</td>
                                 <td>3%</td>
                              </tr>
                              <tr>
                                 <td align="left">Headache</td>
                                 <td>10%</td>
                                 <td>5%</td>
                                 <td>20%</td>
                                 <td>16%</td>
                              </tr>
                              <tr>
                                 <td align="left">Nervousness</td>
                                 <td>15%</td>
                                 <td>11%</td>
                                 <td>6%</td>
                                 <td>8%</td>
                              </tr>
                              <tr>
                                 <td align="left">Gastrointestinal</td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Abdominal/Gastric Disorder</td>
                                 <td>4%</td>
                                 <td>4%</td>
                                 <td>6%</td>
                                 <td>4%</td>
                              </tr>
                              <tr>
                                 <td align="left">Diarrhea</td>
                                 <td>0</td>
                                 <td>1%</td>
                                 <td>5%</td>
                                 <td>1%</td>
                              </tr>
                              <tr>
                                 <td align="left">Nausea/Vomiting</td>
                                 <td>10%</td>
                                 <td>1%</td>
                                 <td>13%</td>
                                 <td>10%</td>
                              </tr>
                              <tr>
                                 <td align="left">Musculoskeletal</td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Aches/Pains</td>
                                 <td>6%</td>
                                 <td>3%</td>
                                 <td>5%</td>
                                 <td>3%</td>
                              </tr>
                              <tr>
                                 <td align="left">Neurological</td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Incoordination</td>
                                 <td>5%</td>
                                 <td>0</td>
                                 <td>2%</td>
                                 <td>*</td>
                              </tr>
                              <tr>
                                 <td align="left">Tremors</td>
                                 <td>3%</td>
                                 <td>1%</td>
                                 <td>5%</td>
                                 <td>4%</td>
                              </tr>
                              <tr>
                                 <td align="left">Other</td>
                                 <td/>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left">Eyes Red/Tired/Itching</td>
                                 <td>3%</td>
                                 <td>0</td>
                                 <td>0</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Head Full-Heavy</td>
                                 <td>3%</td>
                                 <td>0</td>
                                 <td>0</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Malaise</td>
                                 <td>3%</td>
                                 <td>0</td>
                                 <td>0</td>
                                 <td>0</td>
                              </tr>
                              <tr>
                                 <td align="left">Nasal/Sinus Congestion</td>
                                 <td>3%</td>
                                 <td>0</td>
                                 <td>6%</td>
                                 <td>3%</td>
                              </tr>
                              <tr>
                                 <td align="left">Weight Gain</td>
                                 <td>1%</td>
                                 <td>0</td>
                                 <td>5%</td>
                                 <td>2%</td>
                              </tr>
                              <tr>
                                 <td align="left">Weight Loss</td>
                                 <td>*</td>
                                 <td>3%</td>
                                 <td>6%</td>
                                 <td>3%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other adverse reactions occurring at an incidence of &lt;2% with the use of trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hypersalivation, hypomania, impaired memory, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, paresthesia, retrograde ejaculation, shortness of breath, and tachycardia/palpitations. Occasional sinus bradycardia has occurred in long-term studies.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20221125"/>
                  </section>
               </component>
               <component>
                  <section ID="_13047cbc-96a7-38fd-b59b-99bd03fe8f26">
                     <id root="b9a22d0c-d755-7f6e-2e85-9c6f4536b92b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of trazodone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Blood and lymphatic system disorders: </content>hemolytic anemia, leukocytosis</paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiac disorders: </content>cardiospasm, congestive heart failure, conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation. Prolonged QT interval, torsade de pointes, and ventricular tachycardia have been reported at doses of 100 mg per day or less <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_f741940d-8024-3f3c-bad5-7282639ad20b">5.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Endocrine disorders: </content>inappropriate ADH syndrome</paragraph>
                        <paragraph>
                           <content styleCode="bold">Eye disorders: </content>diplopia</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gastrointestinal disorders: </content>increased salivation, nausea/vomiting</paragraph>
                        <paragraph>
                           <content styleCode="bold">General disorders and administration site conditions: </content>chills, edema, unexplained death, weakness </paragraph>
                        <paragraph>
                           <content styleCode="bold">Hepatobiliary disorders: </content>cholestasis, jaundice, hyperbilirubinemia, liver enzyme alterations </paragraph>
                        <paragraph>
                           <content styleCode="bold">Investigations: </content>increased amylase</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism and nutrition disorders: </content>methemoglobinemia</paragraph>
                        <paragraph>
                           <content styleCode="bold">Nervous system disorders: </content>aphasia, ataxia, cerebrovascular accident, extrapyramidal symptoms, grand mal seizures, paresthesia, tardive dyskinesia, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="bold">Psychiatric disorders: </content>abnormal dreams, agitation, anxiety, hallucinations, insomnia, paranoid reaction, psychosis, stupor</paragraph>
                        <paragraph>
                           <content styleCode="bold">Renal and urinary disorders: </content>urinary incontinence, urinary retention</paragraph>
                        <paragraph>
                           <content styleCode="bold">Reproductive system and breast disorders: </content>breast enlargement or engorgement, clitorism, lactation, priapism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_b6388094-f2da-47f5-7312-c218c50322fe">5.6</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Respiratory, thoracic and mediastinal disorders: </content>apnea</paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin and subcutaneous tissue disorders: </content>alopecia, hirsutism, leukonychia, pruritus, psoriasis, rash, urticaria</paragraph>
                        <paragraph>
                           <content styleCode="bold">Vascular disorders: </content>vasodilation</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">
               <id root="f0dcc2a1-dc1c-dacd-0edc-d7139597568c"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20170731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>CNS Depressants: Trazodone may enhance effects of alcohol, barbiturates, or other CNS depressants (<linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>).</item>
                           <item>CYP3A4 Inhibitors: Consider Trazodone dose reduction based on tolerability (<linkHtml href="#_a3d77fa7-a1fa-3c76-8509-132a71f296d7">2.5</linkHtml>, <linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>).</item>
                           <item>CYP3A4 Inducers: Increase in Trazodone dosage may be necessary (<linkHtml href="#_a3d77fa7-a1fa-3c76-8509-132a71f296d7">2.5</linkHtml>, <linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>).</item>
                           <item>Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels (<linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>).</item>
                           <item>Warfarin: Monitor for increased or decreased prothrombin time (<linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">
                     <id root="6b3251ff-839e-888e-6914-a77c3b450de9"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1 Drugs Having Clinically Important Interactions With Trazodone Hydrochloride Tablets</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Table 3: Clinically Important Drug Interactions with Trazodone Hydrochloride Tablets</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>The concomitant use of MAOIs and serotonergic drugs including trazodone increases the risk of serotonin syndrome.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Trazodone is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue <content styleCode="italics">[see Contraindications (<linkHtml href="#_e2fc53b8-049e-0ed8-850a-0ad92a847db7">4</linkHtml>), Dosage and Administration (<linkHtml href="#_c8dfdc15-ea96-18b4-0f7b-97624c18a3d5">2.3</linkHtml>, <linkHtml href="#_9b11e965-1b64-f03b-b1b2-964a8b43597d">2.4</linkHtml>), and Warnings and Precautions <linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">(5.2</linkHtml>)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Other Serotonergic Drugs</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>The concomitant use of serotonergic drugs including trazodone and other serotonergic drugs increases the risk of serotonin syndrome.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Monitor patients for signs and symptoms of serotonin syndrome, particularly during trazodone initiation. If serotonin syndrome occurs, consider discontinuation of trazodone and/or concomitant serotonergic drugs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Antiplatelet Agents and Anticoagulants</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>Serotonin release by platelets plays an important role in hemostasis. The concurrent use of an antiplatelet agent or anticoagulant with trazodone may potentiate the risk of bleeding.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Inform patients of the increased risk of bleeding with the concomitant use of trazodone and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating or discontinuing trazodone <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_a0b9d8cd-491b-71dd-95e2-ada75b696918">5.5</linkHtml>)]</content>.</td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>warfarin, rivaroxaban, dabigatran, clopidogrel</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>The concomitant use of trazodone and strong CYP3A4 inhibitors increased the exposure of trazodone compared to the use of trazodone alone.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>If trazodone is used with a potent CYP3A4 inhibitor, the risk of adverse reactions, including cardiac arrhythmias, may be increased and a lower dose of trazodone should be considered <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_a3d77fa7-a1fa-3c76-8509-132a71f296d7">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#_f741940d-8024-3f3c-bad5-7282639ad20b">5.3</linkHtml>)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>itraconazole, ketoconazole, clarithromycin, indinavir</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Strong CYP3A4 Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>The concomitant use of trazodone and strong CYP3A4 inducers decreased the exposure of trazodone compared to the use of trazodone alone.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking CYP3A4 inducers <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_a3d77fa7-a1fa-3c76-8509-132a71f296d7">2.5</linkHtml>)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>rifampin, carbamazepine, phenytoin, St. John’s wort</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Digoxin and Phenytoin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>Digoxin and phenytoin are narrow therapeutic index drugs. Concomitant use of trazodone can increase digoxin or phenytoin concentrations.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Measure serum digoxin or phenytoin concentrations before initiating concomitant use of trazodone. Continue monitoring and reduce digoxin or phenytoin dose as necessary.</td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>digoxin, phenytoin</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">Central Nervous System (CNS) Depressants</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>Trazodone may enhance the response CNS depressants.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Patients should be counseled that trazodone may enhance the response to alcohol, barbiturates, and other CNS depressants.</td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>alcohol, barbiturates</td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">QT Interval Prolongation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Clinical Impact:</td>
                                 <td>Concomitant use of drugs that prolong the QT interval may add to the QT effects of trazodone and increase the risk of cardiac arrhythmia.</td>
                              </tr>
                              <tr>
                                 <td>Intervention:</td>
                                 <td>Avoid the use of trazodone in combination with other drugs known to prolong QTc <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_f741940d-8024-3f3c-bad5-7282639ad20b">5.3</linkHtml>)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Examples:</td>
                                 <td>Class 1A antiarrhythmics: quinidine, procainamide, disopyramide; Class 3 antiarrhythmics: amiodarone, sotalol; Antipsychotics: ziprasidone, chlorpromazine, thioridazine; Antibiotics: gatifloxacin</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20221125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_41ab5604-d384-ff60-9ab4-da67003fd981">
               <id root="015d0ee7-a07b-be8f-ed83-cffdfd919882"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20181129"/>
               <component>
                  <section ID="_11c1e4a1-87c7-1eaf-e648-c9504a38dd36">
                     <id root="6dba2601-1487-b72b-3c2d-955631799e13"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <linkHtml href="#BOXED_WARNING"/>
                           <linkHtml href="#BOXED_WARNING"/>
                           <linkHtml href="#BOXED_WARNING"/>
                           <content styleCode="bold italics"/>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405- 6185 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published prospective cohort studies, case series, and case reports over several decades with trazodone use in pregnant women have not identified any drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data).</paragraph>
                        <paragraph>Trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in the rat when given at dose levels approximately 7.3 to 11 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m<sup>2</sup> basis. There was also an increase in congenital anomalies in the rabbit at approximately 7.3 to 22 times the MRHD on a mg/m<sup>2</sup> basis (see Data).</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryofetal risk</content>
                        </paragraph>
                        <paragraph>A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression that women who continued antidepressants. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Human Data</paragraph>
                        <paragraph>While available studies cannot definitively establish the absence of risk, published data from prospective cohort studies, case series, and case reports over several decades have not identified an association with trazodone use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. All available studies have methodological limitations, including small sample size and inconsistent comparator groups.</paragraph>
                        <paragraph>Animal Data</paragraph>
                        <paragraph>No teratogenic effects were observed when trazodone was given to pregnant rats and rabbits during the period of organogenesis at oral doses up to 450 mg/kg/day. This dose is 11 and 22 times, in rats and rabbits, respectively, the maximum recommended human dose (MRHD) of 400 mg/day  in adults on a mg/m<sup>2</sup> basis. Increased fetal resorption and other adverse effects on the fetus in rats at 7.3 to 11 times the MRHD and increase in congenital anomalies in rabbits at 7.3 to 22 times the MRHD on a mg/m<sup>2</sup> basis were observed. No further details on these studies are available.</paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20181129"/>
                  </section>
               </component>
               <component>
                  <section ID="_8e9fc91f-7153-73fe-8433-c15eef58ba66">
                     <id root="f7c295eb-776f-0737-4b2e-5e1cc2c34554"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Risk Summary</content>
                        </paragraph>
                        <paragraph>Data from published literature report the transfer of trazodone into human milk. There are no data on the effect of trazodone on milk production. Limited data from postmarketing reports have not identified and association of adverse effects on the breastfed child.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for trazodone and any potential adverse effects on the breastfed child from trazodone or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20181129"/>
                  </section>
               </component>
               <component>
                  <section ID="_0d30fd8a-cf84-c9dd-26ea-2b957071369e">
                     <id root="a59e831a-d518-f0cd-b358-9b59506d7c82"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in the pediatric population have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients <content styleCode="italics">[see <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>, Warnings and Precautions (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_57b1803e-40ca-bb02-a96b-bdff5f52927a">
                     <id root="eeb3a412-30df-ccab-6a77-98a051b61b23"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Reported clinical literature and experience with trazodone has not identified differences in responses between elderly and younger patients. However, as experience in the elderly with trazodone hydrochloride is limited, it should be used with caution in geriatric patients.</paragraph>
                        <paragraph>Serotonergic antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_0bd0cb9b-1a1b-1fa6-8102-5bb19f200b4f">5.11</linkHtml>)].</content>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_1709eb36-a93d-8e3e-da84-af9e178b241b">
                     <id root="487da15f-e7b9-c69d-9c34-eb16846f999f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Trazodone has not been studied in patients with renal impairment. Trazodone should be used with caution in this population.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_65142990-5ae7-903c-9b1b-da44eb78095a">
                     <id root="2d81971b-ed22-eede-a03b-c14886b892ee"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Trazodone has not been studied in patients with hepatic impairment. Trazodone should be used with caution in this population.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_ac340c63-3c62-b9aa-7382-fa84da8c35dd">
               <id root="d47cec10-65de-392a-4cf6-da27f9c6553c"/>
               <code code="42227-9" displayName="DRUG ABUSE AND DEPENDENCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">9 DRUG ABUSE AND DEPENDENCE</content>
               </title>
               <effectiveTime value="20170731"/>
               <component>
                  <section ID="_9c7b4f68-2dea-bd1a-6ac7-8f83a769ab66">
                     <id root="e8404b4d-9d27-bf16-ae0f-544816edb303"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Trazodone hydrochloride tablets are not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_14799197-33d9-5a62-76cc-f2d6621c3f32">
                     <id root="1bc7db00-9158-c47a-fc52-2dcc123323fe"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Although trazodone hydrochloride has not been systematically studied in preclinical or clinical studies for its potential for abuse, no indication of drug-seeking behavior was seen in the clinical studies with trazodone hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_18861b9f-09eb-3b23-9780-609bc4fe1030">
               <id root="22ed14b5-592e-62c0-ae95-188c05a01099"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Death from overdose has occurred in patients ingesting trazodone and other CNS depressant drugs concurrently (alcohol; alcohol and chloral hydrate and diazepam; amobarbital; chlordiazepoxide; or meprobamate).</paragraph>
                  <paragraph>The most severe reactions reported to have occurred with overdose of trazodone alone have been priapism, respiratory arrest, seizures, and ECG changes, including QT prolongation and syndrome of inappropriate antidiuretic hormone secretion (SIADH). The reactions reported most frequently have been drowsiness and vomiting. Overdosage may cause an increase in incidence or severity of any of the reported adverse reactions.</paragraph>
                  <paragraph>There is no specific antidote for trazodone hydrochloride overdose.</paragraph>
                  <paragraph>In managing overdosage, consider the possibility of multiple drug involvement. For current information on the management of poisoning or overdose, contact a poison control center (1-800-222-1222 or www.poison.org).</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="_A915EFB2-FA91-102A-E03C-B5BA3B065AA5">
               <id root="de1df519-b447-6e1b-5615-1a4723b7b6a4"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Trazodone hydrochloride is an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. Trazodone hydrochloride is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4, 3-a]pyridin-3(2<content styleCode="italics">H</content>)-one hydrochloride. It is a white odorless crystalline powder which is freely soluble in water. The structural formula is represented as follows</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM989305667513"/>
                  </paragraph>
                  <paragraph>Each tablet, for oral administration, contains 50 mg, 100 mg, 150 mg or 300 mg of trazodone hydrochloride, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, and sodium starch glycolate.</paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20221124"/>
            </section>
         </component>
         <component>
            <section ID="_1f95db56-0456-61e7-d566-c5c835c4a47f">
               <id root="140a2885-fc77-4c17-787c-2ca47800b919"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20170731"/>
               <component>
                  <section ID="_7c97208b-cc7c-fe22-91d7-20b108e25711">
                     <id root="6e712c78-9cb7-3fff-5aed-fea20abba7fd"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic transmission and its role in trazodone’s antidepressant effect is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_3683cedc-417a-dbf9-f0d5-0b78898b323a">
                     <id root="a29b6ff6-8e53-2b15-a54e-75064095d4c9"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Preclinical studies have shown that trazodone selectively inhibits neuronal reuptake of serotonin (Ki = 367 nM) and acts as an antagonist at 5-HT-2A (Ki = 35.6 nM) serotonin receptors. Trazodone is also an antagonist at several other monoaminergic receptors including 5-HT2B (Ki = 78.4 nM), 5-HT2C (Ki = 224 nM), α1A (Ki = 153 nM), α2C (Ki = 155 nM) receptors and it is a partial agonist at 5-­HT1A (Ki = 118 nM) receptor.</paragraph>
                        <paragraph>Trazodone antagonizes alpha 1-adrenergic receptors, a property which may be associated with postural hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
               <component>
                  <section ID="_f627de6e-69f2-3166-f3c0-3a99e42180b9">
                     <id root="44cbf635-306f-086e-06ed-91546eca1dc1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Absorption</content>
                        </paragraph>
                        <paragraph>In humans, trazodone hydrochloride is absorbed after oral administration without selective localization in any tissue. When trazodone hydrochloride is taken shortly after ingestion of food, there may be an increase in the amount of drug absorbed, a decrease in maximum concentration and a lengthening in the time to maximum concentration. Peak plasma levels occur approximately one hour after dosing when trazodone hydrochloride is taken on an empty stomach or 2 hours after dosing when taken with food.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Metabolism</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro </content>studies in human liver microsomes show that trazodone is metabolized, via oxidative cleavage, to an active metabolite, m-chlorophenylpiperazine (mCPP) by CYP3A4. Other metabolic pathways that may be involved in the metabolism of trazodone have not been well characterized. Trazodone is extensively metabolized; less than 1% of an oral dose is excreted unchanged in the urine.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Elimination</content>
                        </paragraph>
                        <paragraph>In some patients trazodone may accumulate in the plasma.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Protein Binding</content>
                        </paragraph>
                        <paragraph>Trazodone is 89 to 95% protein bound <content styleCode="italics">in vitro</content> at concentrations attained with therapeutic doses in humans.<content styleCode="bold italics"/>
                           <content styleCode="bold italics"/>
                           <content styleCode="bold italics"/>
                           <content styleCode="bold italics"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6f5dd153-267d-2be7-238e-04ebd57499c5">
               <id root="a3ac731b-45eb-d320-1876-cb833f67324e"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20181129"/>
               <component>
                  <section ID="_50f28ca1-99e9-e210-9d09-8b65d5ef729b">
                     <id root="48919cc5-0759-0763-fcd2-adce8d1dc38f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>No drug- or dose-related occurrence of carcinogenesis was evident in rats receiving trazodone in daily oral doses up to 7.3 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Mutagenesis</content>
                        </paragraph>
                        <paragraph>No genotoxicity studies were conducted with trazodone.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Trazodone has no effect on fertility in rats at doses up to 7.3 times the MRHD in adults on a mg/m<sup>2</sup> basis.</paragraph>
                     </text>
                     <effectiveTime value="20221129"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_f52111db-dd2d-56f1-ba2e-90936122fa37">
               <id root="c789b936-b7f3-c630-3d60-4402ca92882c"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">14 CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>The efficacy and safety of trazodone hydrochloride were established from <content styleCode="underline">inpatient and outpatient</content> trials of the trazodone immediate release formulation in the treatment of major depressive disorder.</paragraph>
               </text>
               <effectiveTime value="20170731"/>
            </section>
         </component>
         <component>
            <section ID="_18b6d2bd-f1d8-e106-4998-2c7c98e1e837">
               <id root="4165c149-0dcb-c73e-2fbe-91f622811bf3"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Trazodone hydrochloride tablets, USP 50 mg are available for oral administration as white, round, biconvex, tablets. Engraved “APO” bisect “T50” on one side, other side plain. </paragraph>
                  <paragraph>Bottles of 100 (NDC 60505-2653-1) </paragraph>
                  <paragraph>Trazodone hydrochloride tablets, USP 100 mg are available for oral administration as white, round, biconvex, tablets. Engraved “APO” bisect “T100” on one side, other side plain. </paragraph>
                  <paragraph>Bottles of 100 (NDC 60505-2654-1) </paragraph>
                  <paragraph>Trazodone hydrochloride tablets, USP 150 mg are available for oral administration as white, oval, flat faced beveled-edge tablets with a full bisect and 2 partial trisects. Engraved “APO” bisect “T150” on one side, and “50 50 50” on the other side. </paragraph>
                  <paragraph>Bottles of 100 (NDC 60505-2655-1) </paragraph>
                  <paragraph>Directions for using the correct score when breaking the tablet, please refer to the following: </paragraph>
                  <paragraph>- For 50 mg, break the score on either the left or right side of the tablet (one-third of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM557716188616"/>
                  </paragraph>
                  <paragraph>- For 75 mg, break the score down the middle of the tablet (one-half of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM713385749530"/>
                  </paragraph>
                  <paragraph>- For 100 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM429238456859"/>
                  </paragraph>
                  <paragraph>- For 150 mg, use the entire tablet. </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM701672054080"/>
                  </paragraph>
                  <paragraph>Trazodone hydrochloride tablets, USP 300 mg are available for oral administration as white, oval, flat faced beveled-edge tablets with a full bisect and 2 partial trisects. Engraved “APO” bisect “T300” on one side, and “100 100 100” on the other side with the middle “100” perpendicular to the others. </paragraph>
                  <paragraph>Bottles of 100 (NDC 60505-2659-1) </paragraph>
                  <paragraph>Directions for using the correct score when breaking the tablet, please refer to the following: </paragraph>
                  <paragraph>- For 100 mg, break the score on either the left or right side of the tablet (one-third of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM477102318795"/>
                  </paragraph>
                  <paragraph> - For 150 mg, break the score down the middle of the tablet (one-half of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM713385749530"/>
                  </paragraph>
                  <paragraph>- For 200 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet). </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM642721831157"/>
                  </paragraph>
                  <paragraph>- For 300 mg, use the entire tablet. </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM593807962266"/>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Dispense with a child-resistant closure in a tight, light-resistant container.</paragraph>
               </text>
               <effectiveTime value="20221124"/>
            </section>
         </component>
         <component>
            <section ID="_3cf560c6-e24c-8ab7-09bc-506666d07baf">
               <id root="4388b3d8-3668-c1ec-05a4-0e110e6120e0"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Suicidal Thoughts and Behaviors</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Advise </content>patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider <content styleCode="italics">[see <linkHtml href="#BOXED_WARNING"> Box Warning </linkHtml> and Warnings and Precautions (<linkHtml href="#_d4289aff-5958-dcf0-0440-cc71f7bc082d">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage and Administration</content>
                  </paragraph>
                  <paragraph>Advise patients that trazodone hydrochloride tablets should be taken shortly after a meal or light snack. Advise patients regarding the importance of following dosage titration instructions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_8f8248bc-6ea9-4ef1-3a17-469f187f7e09">2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of trazodone with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Patients should contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_33c063b9-30e5-1254-930d-96a81239f17b">5.2</linkHtml>) and Drug Interactions (<linkHtml href="#_ae6051b9-9d2d-a9eb-273c-7cdfd31c8812">7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Activation of Mania/Hypomania</content>
                  </paragraph>
                  <paragraph>Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_5721d907-539e-4548-d3ca-2940e4c2af16">5.7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Increased Risk of Bleeding</content>
                  </paragraph>
                  <paragraph>Inform patients about the concomitant use of trazodone with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use of drugs that interfere with serotonin reuptake and these medications has been associated with an increased risk of bleeding. Advise them to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_a0b9d8cd-491b-71dd-95e2-ada75b696918">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discontinuation Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients not to abruptly discontinue trazodone hydrochloride tablets and to discuss any tapering regimen with their healthcare provider. Adverse reactions can occur when trazodone hydrochloride tablets is discontinued <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ce899574-ede6-067b-51f8-def9ab8193a1">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Concomitant Medications</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their health care providers if they are taking, or plan to take any prescription or over-the-counter medications since there is a potential for interactions <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_e6d91686-6ca6-81ed-ffd1-6fc3130ab6b2">7.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during therapy with trazodone hydrochloride tablets. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to trazodone hydrochloride tablets during pregnancy <content styleCode="italics">[see Use in Special Populations (<linkHtml href="#_11c1e4a1-87c7-1eaf-e648-c9504a38dd36">8.1</linkHtml>)]. </content>
                  </paragraph>
                  <paragraph>Dispense with Medication Guide available at <content styleCode="underline">https://www.apotex.com/products/us/mg.asp</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC. <br/>TRAZODONE HYDROCHLORIDE TABLETS, USP <br/>50 mg, 100 mg, 150 mg and 300 mg</content>
                  </paragraph>
                  <table width="30%">
                     <tbody>
                        <tr>
                           <td>Manufactured by</td>
                           <td>Manufactured For</td>
                        </tr>
                        <tr>
                           <td>Apotex Inc. </td>
                           <td>Apotex Corp.</td>
                        </tr>
                        <tr>
                           <td>Toronto, Ontario</td>
                           <td>Weston Florida</td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9</td>
                           <td>33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Rev. 9</paragraph>
               </text>
               <effectiveTime value="20250317"/>
            </section>
         </component>
         <component>
            <section ID="_BB67BC1E-CE05-A8F0-AD02-F0783976DC58">
               <id root="8aa4f8f4-b2c7-0fed-d221-6afcee489dfa"/>
               <code code="42231-1" displayName="SPL MEDGUIDE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">MEDICATION GUIDE </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Trazodone hydrochloride tablets, USP</content>
                     <content styleCode="bold">, for oral use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(traz' oh done hye'' droe klor' ide)</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Medication Guide available at<content styleCode="underline"> </content>
                     <content styleCode="underline">https://www.apotex.com/products/us/mg.asp</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Antidepressant medicines, depression or other serious mental illnesses, and suicidal thoughts or actions: Talk to your healthcare provider about:<content styleCode="bold"/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <list>
                     <item>All risks and benefits of treatment with antidepressant medicines</item>
                     <item>All treatment choices for depression or other serious mental illnesses</item>
                  </list>
                  <paragraph>1. <content styleCode="bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment</content>.<content styleCode="bold"/>
                  </paragraph>
                  <paragraph>2. <content styleCode="bold">Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions</content>. <content styleCode="bold">Some people may have a higher risk of having suicidal thoughts or actions</content>. These include people who have or have a family history of <content styleCode="bold"/>bipolar illness (also called manic- depressive illness) or suicidal thoughts <content styleCode="bold"/>or actions.<content styleCode="bold"/>
                  </paragraph>
                  <paragraph>3. <content styleCode="bold">How can I watch for and try to prevent suicidal thoughts and actions?</content>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <list>
                     <item>Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</item>
                     <item>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings.</item>
                     <item>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms.<paragraph/>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:</content>
                  </paragraph>
                  <list>
                     <item>Thoughts about suicide or dying </item>
                     <item>Attempts to commit suicide<content styleCode="bold"/>
                     </item>
                     <item>New or worse depression<content styleCode="bold"/>
                     </item>
                     <item>New or worse anxiety<content styleCode="bold"/>
                     </item>
                     <item>Feeling very agitated or restless<content styleCode="bold"/>
                     </item>
                     <item>Panic attacks<content styleCode="bold"/>
                     </item>
                     <item>Trouble sleeping (insomnia)<content styleCode="bold"/>
                     </item>
                     <item>New or worse irritability<content styleCode="bold"/>
                     </item>
                     <item>Acting aggressive, being angry or violent<content styleCode="bold"/>
                     </item>
                     <item>Acting on dangerous impulses<content styleCode="bold"/>
                     </item>
                     <item>An extreme increase in activity and talking (mania)<content styleCode="bold"/>
                     </item>
                     <item>Other unusual changes in behavior or mood<content styleCode="italics"/>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What else do I need to know about antidepressant medicines?</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">Never stop an antidepressant medicine without first talking to a healthcare provider</content>. Stopping an antidepressant medicine suddenly can <content styleCode="bold"/>cause other symptoms.<content styleCode="bold"/>
                     </item>
                     <item>
                        <content styleCode="bold">Antidepressants are medicines used to treat depression and other illnesses. </content>It is important to discuss all the risks of treating depression and <content styleCode="bold"/>also the risks of not treating it. You should discuss all treatment choices <content styleCode="bold"/>with your healthcare provider, not just the use of antidepressants.<content styleCode="bold"/>
                     </item>
                     <item>
                        <content styleCode="bold">Antidepressant medicines have other side effects</content>. Talk to your healthcare provider about the side effects of your medicines.</item>
                     <item>
                        <content styleCode="bold">Antidepressant medicines can interact with other medicines. </content>Know all of the medicines that you take. Keep a list of all medicines to show your healthcare provider. Do not start new medicines without first checking with your healthcare provider.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>It is not known if trazodone is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Trazodone hydrochloride tablets are a prescription medicine used in adults to treat major depressive disorder (MDD). Trazodone belongs to a class of medicines known as SSRIs (or selective serotonin reuptake inhibitors).</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                     <content styleCode="bold">Do not take trazodone hydrochloride tablets:</content>
                  </paragraph>
                  <list>
                     <item>If you take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid, and intravenous methylene blue.</item>
                     <item>Do not take an MAOI within 2 weeks of stopping trazodone hydrochloride tablets unless directed to do so by your healthcare provider.</item>
                     <item>Do not start trazodone hydrochloride tablets if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcare provider.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before you take trazodone hydrochloride tablets tell your healthcare provider about all of your medical conditions, including if you:</content>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <list>
                     <item>have heart problems, including QT prolongation or a family history of it</item>
                     <item>have ever had a heart attack</item>
                     <item>have bipolar disorder</item>
                     <item>have liver or kidney problems</item>
                     <item>have other serious medical conditions</item>
                     <item>are pregnant or plan to become pregnant. It is not known if trazodone hydrochloride tablets harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take trazodone hydrochloride tablets.</item>
                     <item>If you become pregnant during treatment with trazodone hydrochloride tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-6185.</item>
                     <item>are breastfeeding or plan to breastfeed. Trazodone hydrochloride passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take trazodone hydrochloride tablets.</item>
                     <item>have taken a Monoamine Oxidase Inhibitor (MAOI) or if you have stopped taking an MAOI in the last 2 weeks.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>
                     </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using trazodone hydrochloride tablets with certain other medicines can affect each other causing serious side effects.</paragraph>
                  <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                  <list>
                     <item>triptans used to treat migraine headache</item>
                     <item>medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, buspirone, or antipsychotics</item>
                     <item>tramadol</item>
                     <item>over-the-counter supplements such as tryptophan or St. John’s Wort</item>
                     <item>nonsteroidal anti-inflammatory drugs (NSAIDS)</item>
                     <item>aspirin</item>
                     <item>warfarin (Coumadin, Jantoven)</item>
                     <item>phenytoin (Mesantoin)</item>
                     <item>diuretics</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"/>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <list>
                     <item>Take trazodone hydrochloride tablets exactly as your healthcare provider tells you.</item>
                     <item>Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.</item>
                     <item>If you feel drowsy after taking trazodone hydrochloride tablets, talk to your healthcare provider. Your healthcare provider may change your dose or the time of day you take your trazodone hydrochloride tablets.</item>
                     <item>Do not stop taking trazodone hydrochloride tablets without talking to your healthcare provider.</item>
                     <item>Trazodone hydrochloride tablets should be swallowed whole or broken in half along the score line. Do not chew or crush trazodone hydrochloride tablets. Tell your healthcare provider if you cannot swallow trazodone either whole or as a half tablet.</item>
                     <item>If you take too much trazodone hydrochloride, call your healthcare provider, your Poison Control Center at 1-800-222-1222, or go to the nearest emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <list>
                     <item>Do not drive, operate heavy machinery, or do other dangerous activities until you know how trazodone hydrochloride tablets affect you. Trazodone hydrochloride tablets can slow your thinking and motor skills.</item>
                     <item>Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking trazodone hydrochloride tablets until you talk with your healthcare provider. Trazodone hydrochloride tablets may make your sleepiness or dizziness worse if you take it with alcohol or other medicines that cause sleepiness or dizziness.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Trazodone hydrochloride tablets can cause serious side effects or death, including: </content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">See “What is the most important information I should know about trazodone hydrochloride tablets?”</content>
                     </item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="bold">Serotonin syndrome.</content> Symptoms of serotonin syndrome include: agitation, hallucinations, problems with coordination, fast heartbeat, tight muscles, trouble walking, sweating, fever, nausea, vomiting, and diarrhea. </item>
                     <item>
                        <content styleCode="bold">Irregular or fast heartbeat or faint (QT prolongation)</content>
                     </item>
                     <item>
                        <content styleCode="bold">Low blood pressure. </content>You feel dizzy or faint when you change positions (go from sitting to standing)</item>
                     <item>
                        <content styleCode="bold">Unusual bruising or bleeding</content>
                     </item>
                     <item>
                        <content styleCode="bold">Erection lasting for more than 6 hours (priapism)</content>
                     </item>
                     <item>
                        <content styleCode="bold">Feeling high or in a very good mood, then becoming irritable, or having too much energy, feeling like you have to keep talking or do not sleep (mania).</content>
                     </item>
                     <item>
                        <content styleCode="bold">Withdrawal symptoms. </content>Symptoms of withdrawal can include anxiety, agitation, and sleep problems. Do not stop taking trazodone hydrochloride tablets without talking to your healthcare provider.</item>
                     <item>
                        <content styleCode="bold">Visual problems.</content>
                        <list>
                           <item>eye pain</item>
                           <item>changes in vision</item>
                           <item>swelling or redness in or around the eye<paragraph>
                                 <br/>Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.<br/>
                                 <br/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">Low sodium in your blood (hyponatremia). </content>Symptoms of hyponatremia include: headache, feeling weak, feeling confused, trouble concentrating, memory problems and feeling unsteady when you walk.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"/>Get medical help right away, if you have any of the symptoms listed above.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of trazodone hydrochloride tablets include:</content>
                  </paragraph>
                  <list>
                     <item>swelling </item>
                     <item>blurred vision </item>
                     <item>dizziness </item>
                     <item>sleepiness </item>
                     <item>tiredness </item>
                     <item>diarrhea </item>
                     <item>stuffy nose </item>
                     <item>weight loss</item>
                  </list>
                  <paragraph>These are not all the possible side effects of trazodone hydrochloride tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store trazodone hydrochloride tablets?</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <list>
                     <item>Store trazodone hydrochloride tablets between 20°C to 25°C (68°F to 77°F).</item>
                     <item>Keep in tight container</item>
                     <item>Keep out of the light</item>
                     <item>Safely throw away medicine that is out of date or no longer needed.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep trazodone hydrochloride tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of trazodone hydrochloride tablets.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use trazodone hydrochloride tablets for a condition for which it was not prescribed. Do not give trazodone hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about trazodone hydrochloride tablets that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>For more information contact Apotex Corp., Drug Safety at 1-800-706-5575.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in trazodone hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Active ingredient: trazodone hydrochloride, USP</paragraph>
                  <paragraph>Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, and sodium starch glycolate.</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC. <br/>
                     </content>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS, USP<br/>
                     </content>
                     <content styleCode="bold">50 mg, 100 mg, 150 mg and 300 mg </content>
                  </paragraph>
                  <table width="30%">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by</content>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured For</content>
                           </td>
                        </tr>
                        <tr>
                           <td>Apotex Inc. </td>
                           <td>Apotex Corp.</td>
                        </tr>
                        <tr>
                           <td>Toronto, Ontario</td>
                           <td>Weston Florida</td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9</td>
                           <td>33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Revised: March 2025</paragraph>
                  <paragraph>Rev. 9</paragraph>
               </text>
               <effectiveTime value="20250317"/>
            </section>
         </component>
         <component>
            <section ID="_be313934-c37c-8faa-3a4e-79e600d39f02">
               <id root="3ea488bc-303a-a057-22e8-a7d8673d3f4a"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 50 mg BOTTLE LABEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-2653-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS USP</content>
                  </paragraph>
                  <paragraph>50 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>100 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM107749710029"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
         <component>
            <section ID="_df280c21-146d-16a1-ec55-4872d800397e">
               <id root="ec76ef57-54d0-71b4-ed7a-59fc298c7b5a"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 100 mg BOTTLE LABEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-2654-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS USP</content>
                  </paragraph>
                  <paragraph>100 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>100 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM554913463851"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
         <component>
            <section ID="_c1704041-ba6d-98b2-2521-fd70863aec98">
               <id root="3d3bc5df-5589-2cdc-2f76-ccdcee7db36e"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 150 mg BOTTLE LABEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-2655-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS USP</content>
                  </paragraph>
                  <paragraph>150 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>100 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM185815916677"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
         <component>
            <section ID="_24086073-5832-adca-45f7-eaffd1a1e0c9">
               <id root="1cce9d23-651e-3294-2ddd-35be87c8c785"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 150 mg BOTTLE LABEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-4089-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS USP</content>
                  </paragraph>
                  <paragraph>150 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>12 Bottles x 30 Tablets per bottle</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM264852694410"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
         <component>
            <section ID="_547e1381-46ca-725b-7518-ebbf582d5170">
               <id root="7af2915d-8de3-53ea-5242-70c0fdbc7b04"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 300 mg BOTTLE LABEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP. </content>NDC 60505-2659-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">TRAZODONE HYDROCHLORIDE TABLETS USP</content>
                  </paragraph>
                  <paragraph>300 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>100 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM57659932193"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>